Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider,
With FDA nod, AstraZeneca's FluMist becomes first self-administered flu vaccine
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17.
AstraZeneca FluMist gets USFDA nod for self-administered influenza vaccine
AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a needle-free nasal spray, was approved to be self-administered by adults
US FDA approves AstraZeneca's flu vaccine for self-administration
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for self-administration, making it the first of its kind that patients can give themselves.
FDA approves ‘FluMist,' says no healthcare provider needed
FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the regulator said.
FDA Approves First Flu Vaccine You Give Yourself at Home
It's a "new option for receiving a safe and effective seasonal influenza vaccine potentially with greater convenience, flexibility and accessibility for individuals and families," said Dr. Peter Marks,
1d
AstraZeneca falls Friday, still outperforms market
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
1d
AstraZeneca: Poised for Growth with Promising Innovation Pipeline and Attractive Valuation
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
FierceBiotech
7d
ESMO: AstraZeneca steps out from Daiichi's shadow, posting data on ADC rivals to AbbVie, Pfizer
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
STAT
5d
News from ESMO: An AstraZeneca win in bladder cancer, and more
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
5d
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
4d
AstraZeneca falls Tuesday, underperforms market
AstraZeneca PLC AZN shares inched down 0.40% to £119.68 Tuesday, on what proved to be an all-around great trading session for ...
STAT
6d
AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study
If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...
Business Insider
3d
AstraZeneca: A Buy Rating Based on Promising Pipeline and Regulatory Prospects
AstraZeneca
(AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on ...
1d
AstraZeneca India to launch Palivizumab in Oct 2024, stocks trade flat
AstraZeneca Pharma India to launch Palivizumab in India, a drug to prevent RSV in high-risk children. Stocks rise.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
FluMist
Dow Jones Industrial Average
Trade
Food and Drug Administration
ADR
Feedback